|1.||Binaschi, Monica: 3 articles (11/2007 - 12/2002)|
|2.||Rabasseda, X: 3 articles (09/2006 - 01/2003)|
|3.||Prous, J R: 3 articles (09/2006 - 01/2003)|
|4.||Maggi, C A: 2 articles (09/2008 - 02/2001)|
|5.||Manzini, S: 2 articles (09/2008 - 02/2001)|
|6.||Maggi, Carlo Alberto: 2 articles (11/2007 - 09/2005)|
|7.||Manzini, Stefano: 2 articles (11/2007 - 09/2005)|
|8.||Bayes, M: 2 articles (09/2006 - 05/2005)|
|9.||Vermorken, J B: 2 articles (01/2006 - 03/2002)|
|10.||Camarda, Grazia: 2 articles (09/2005 - 12/2002)|
03/01/2002 - "Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group."
11/01/2007 - "Sabarubicin accumulates in the mitochondria of A2780 human ovarian tumor cells. "
12/01/2003 - "Menarini is developing the anthracycline aminodisaccharide MEN-10755 for the potential treatment of solid tumors. "
11/01/1998 - "Tumors with typical multidrug-resistant phenotype were excluded because MEN 10755 was found unable to overcome resistance mediated by transport systems. "
11/01/1998 - "In the present study, to better support the pharmacological interest of MEN 10755, we extended the preclinical evaluation of antitumor efficacy to a large panel of 16 human tumor xenografts, which originated from different clinicopathological types. "
12/10/2002 - "Nuclear factor-kappaB, induced in human carcinoma cell line A2780 by the new anthracycline men 10755, is devoid of transcriptional activity."
11/01/1998 - "In one of these tumors (MX-1 breast carcinoma), we examined the ability of MEN 10755 to induce phosphorylation of Bcl-2 after a single treatment with therapeutic doses. "
11/01/1998 - "In the series of doxorubicin-resistant tumors, MEN 10755 was found effective in 6 of 11 tumors (1 breast, 3 lung, and 2 prostate carcinomas). "
12/10/2002 - "Other human carcinoma cell lines besides A2780 activate NF-kappaB DNA binding in response to MEN 10755 treatment, but again, this binding does not always lead to target gene activation. "
08/20/1997 - "The antitumor activity of this compound (MEN 10755) was studied in a panel of human tumor xenografts, including xenografts of A2780 ovarian tumor cells, MX-1 breast carcinoma cells, and POVD small-cell lung cancer cells. "
|3.||Lung Neoplasms (Lung Cancer)
07/01/2004 - "MEN-10755 is a novel anthracycline analogue that has shown an improved therapeutic efficacy over doxorubicin in animal models, especially in gynaecological and lung cancers and is currently under clinical development for the treatment of solid tumours. "
09/01/2008 - "The antitumour effect of Sabarubicin and DDP association was investigated, in vitro and in vivo, in preclinical models of lung cancer i.e.: the non-small cell lung carcinoma (NSCLC) H460 and the small-cell lung carcinoma (SCLC) GLC4 in terms of synergism, additivity or antagonism in order to establish the best schedule for the combined treatment. "
|4.||Ovarian Neoplasms (Ovarian Cancer)
01/01/2005 - "Sabarubicin showed limited activity in patients with resistant ovarian cancer. "
02/01/2001 - "In the present study, we investigated the mechanisms of cell death induced by doxorubicin (DXR) and the novel disaccharide anthracycline MEN 10755, in a human ovarian cancer cell line (A2780). "
01/01/2005 - "A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer."
01/01/2005 - "The aim of the study was to evaluate the activity and safety profile of sabarubicin in patients with locally advanced or metastatic ovarian cancer failing 1st line platinum and/or taxane based chemotherapy, and relapsing earlier than 6 months after the last chemotherapy. "
02/01/2005 - "Pegylated-coated liposomal formulation doxorubicin (Caelyx) has shown efficacy in metastatic breast cancer and in advanced ovarian cancer; sabarubicin is a third-generation anthracycline with equal or superior potency to doxorubicin or idarubicin in a variety of human tumor cell lines of different histotypes. "
|5.||Prostatic Neoplasms (Prostate Cancer)
01/01/2006 - "Sabarubicin (MEN-10755), a new synthetic anthracycline analogue, was evaluated for safety and efficacy in a multicentre phase II study in patients with advanced hormone refractory prostate cancer (HRPC). "
01/01/2006 - "A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer."
|5.||peginterferon alfa-2a (Pegasys)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)
|4.||Nebulizers and Vaporizers (Inhaler)